Ascletis announces first participants dosed in u.s. phase i clinical study of asc50, a potential best-in-class oral small molecule il-17 inhibitor for the treatment of psoriasis

-  t he phase i trial evaluates the safety, tolerability and preliminary efficacy of asc50 for the treatment of psoriasis. -  preclinical data, including higher oral exposure, longer half-life and strong efficacy, support asc50 as a potential best-in-class once-daily oral agent for the treatment of psoriasis.
ASC Ratings Summary
ASC Quant Ranking